Trans Chromosomics, Inc. (TC)

Foreword

 

　Our company was founded in 2014 to put the research outcomes of basic chromosome researches over 40 years into practical use. The beginning of the application of the chromosomal engineering research to medicine was the development of human mono chromosome library and the chromosome transfer technology. In the 1990's, we succeeded in developing the first fully human antibody-producing mouse in the world through collaboration research with Kirin Brewery Co., Ltd. (present Kyowa Hakko Kirin Co., Ltd.). This result has opened up a new era of antibody drugs. In the next 20 years, the foundation of artificial chromosome engineering technology has been completed, and many state-of-the-art platforms are being constructed for drug discovery to combat intractable diseases. Through extensive use of these technologies, we will strive to reach out, even a day earlier, to patients who suffer from intractable diseases.

Mitsuo Oshimura

CEO